source
- Novartis signs up to $3.2 billion deal with Korea's Alteogen for subcutaneous drug delivery technologyNovartis has entered an option and license agreement with Korean biotech Alteogen to use its ALT-B4 subcutaneous delivery platform, a partnership that could be worth up to $3.2 billion if all optio…
- Medline expands recall of reprocessed electrophysiology and ultrasound catheters due to contamination riskMedline Industries has issued an expanded recall that adds new lots of reprocessed electrophysiology and ultrasound catheters after the FDA identified possible residual particulates in the devices.…